Genitourinary Pathology/Kidney Cancer/Prostate Cancer/Urothelial Carcinoma
Cytopathology/Thyroid Cytopathology
MD Anderson Cancer Center
Houston, TX
Fellowship - Cytopathology
2009
MD Anderson Cancer Center
Houston, TX
Fellowship - Genotourinary Pathology
2008
Loyola University
Maywood, IL
Residency - AP/CP Pathology
2007
University of Belgrade Medical School
Belgrade, Serbia
MD - Medicine
1991
Clinicopathological and molecular comparison of eosinophilic solid and cystic renal cell carcinoma and TFEB-amplified renal cell carcinoma: a comprehensive study of 15 cases.
Clinicopathological and molecular comparison of eosinophilic solid and cystic renal cell carcinoma and TFEB-amplified renal cell carcinoma: a comprehensive study of 15 cases. Histopathology. 2026 Aug 13.
PMID: 42591048
Accuracy of Cytology Diagnosis for Well Differentiated Neuroendocrine Tumors: Assessment by the College of American Pathologists Non-Gynecologic Slide Program.
Accuracy of Cytology Diagnosis for Well Differentiated Neuroendocrine Tumors: Assessment by the College of American Pathologists Non-Gynecologic Slide Program. Arch Pathol Lab Med. 2026 Jun 26.
PMID: 42362197
Penile squamous cell carcinomas with the usual-type morphology can be HPV-associated - Routine p16/HPV testing should be performed in all penile squamous cell carcinomas regardless of morphology.
Penile squamous cell carcinomas with the usual-type morphology can be HPV-associated - Routine p16/HPV testing should be performed in all penile squamous cell carcinomas regardless of morphology. Virchows Arch. 2026 Jun 24.
PMID: 42340386
NFE2L2-mutated urothelial carcinomas frequently show concomitant myxoid and squamous features and have high PD-L1 expression.
NFE2L2-mutated urothelial carcinomas frequently show concomitant myxoid and squamous features and have high PD-L1 expression. Histopathology. 2026 Jun 06.
PMID: 42249733
Association of genomic driver mutation, histologic subtype, and mTORC1 biomarker expression in mTOR pathway-altered renal tumors.
Association of genomic driver mutation, histologic subtype, and mTORC1 biomarker expression in mTOR pathway-altered renal tumors. Hum Pathol. 2026 Sep; 175:106154.
PMID: 42155824
Comprehensive analysis of six MED15::TFE3 renal cell carcinomas including two novel solid MED15::TFE3 renal cell carcinomas, highlighting their morphologic, immunohistochemical and molecular differences from their cystic counterparts.
Comprehensive analysis of six MED15::TFE3 renal cell carcinomas including two novel solid MED15::TFE3 renal cell carcinomas, highlighting their morphologic, immunohistochemical and molecular differences from their cystic counterparts. Virchows Arch. 2026 Sep; 489(3):669-680.
PMID: 42113263
The Many Faces of TPM3::ALK Fusion Renal Cell Carcinoma: Case Report and Review of the Literature.
The Many Faces of TPM3::ALK Fusion Renal Cell Carcinoma: Case Report and Review of the Literature. Int J Surg Pathol. 2026 Aug; 34(5):1241-1246.
PMID: 41885739
Cytomorphologic and molecular characterization of metastatic renal cell carcinoma diagnosed by fine-needle biopsy: a single-institution study.
Cytomorphologic and molecular characterization of metastatic renal cell carcinoma diagnosed by fine-needle biopsy: a single-institution study. J Am Soc Cytopathol. 2026 May-Jun; 15(3):197-206.
PMID: 41904061
PAX8-positive conventional urothelial carcinomas of the urinary bladder and their distinct molecular profiles - A clinicopathologic study of 101 consecutive cases with next-generation sequencing in 20 cases.
PAX8-positive conventional urothelial carcinomas of the urinary bladder and their distinct molecular profiles - A clinicopathologic study of 101 consecutive cases with next-generation sequencing in 20 cases. Histopathology. 2026 Jun; 88(7):1315-1323.
PMID: 41652309
Percutaneous renal mass biopsies with no viable lesional cells - Recognizing different histologic patterns can help predict nondiagnostic vs. true negative biopsy and guide clinical management.
Percutaneous renal mass biopsies with no viable lesional cells - Recognizing different histologic patterns can help predict nondiagnostic vs. true negative biopsy and guide clinical management. Ann Diagn Pathol. 2026 Jun; 82:152607.
PMID: 41520489